1. Clearing the fog: a review of the effects of dietary omega-3 fatty acids and added sugars on chemotherapy-induced cognitive deficits

   • Tonya S. Orchard
   • Monica M. Gaudier-Diaz
   • A. Courtney DeVries

   Review 08 December 2016 Pages: 391 - 398

   

2. Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer

   • Ryoko Saito
   • Yasuhiro Miki
   • Hironobu Sasano

   Preclinical Study 30 November 2016 Pages: 399 - 407

   

3. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status

   • Yul Ri Chung
   • Hyun Jeong Kim
   • So Yeon Park

   Preclinical Study 02 December 2016 Pages: 409 - 420

   

4. Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer

   • Michel van Gelder
   • Ariane Vanclée
   • Gerard M. Bos

   Preclinical Study Open access 03 December 2016 Pages: 421 - 433

   

5. Estimating the OncotypeDX score: validation of an inexpensive estimation tool

   • Anne A. Eaton
   • Catherine E. Pesce
   • Mahmoud El-Tamer

   Clinical trial 07 December 2016 Pages: 435 - 441

   

6. Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?

   • Kyeong Eun Uhm
   • Ji Sung Yoo
   • Ji Hye Hwang

   Clinical trial 08 December 2016 Pages: 443 - 452

   

7. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer

   • Jason D. Robarge
   • Zereunesay Desta
   • N. Lynn Henry

   Clinical trial 09 December 2016 Pages: 453 - 461

   

8. Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients

   • J. Shiao
   • K. M. Thomas
   • D. W. Nathan Kim

   Clinical trial 22 December 2016 Pages: 463 - 471

   

9. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

   • Daigo Yamamoto
   • Nobuaki Sato
   • Katsumasa Kuroi

   Clinical trial 22 December 2016 Pages: 473 - 482

   

10. Does the TNM classification of solitary internal mammary lymph node metastases in breast cancer still apply?

    • V. Habraken
    • T. J. A. van Nijnatten
    • M. L. Smidt

    Epidemiology Open access 03 December 2016 Pages: 483 - 489

    

11. Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians

    • Foluso O. Ademuyiwa
    • Yu Tao
    • Cynthia X. Ma

    Epidemiology 03 December 2016 Pages: 491 - 499

    

12. Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis

    • Song Yao
    • Yali Zhang
    • Marilyn L. Kwan

    Epidemiology 03 December 2016 Pages: 501 - 513

13. Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer

    • Shuling Li
    • Jiannong Liu
    • Allan J. Collins

    Epidemiology 08 December 2016 Pages: 515 - 524

    

14. The impact of doctor–patient communication on patients’ perceptions of their risk of breast cancer recurrence

    • Nancy K. Janz
    • Yun Li
    • Sarah T. Hawley

    Epidemiology 09 December 2016 Pages: 525 - 535

    

15. Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis

    • Bernardo Amadeo Leone
    • Carlos Teodoro Vallejo
    • José Pablo Leone

    Epidemiology 14 December 2016 Pages: 537 - 548

    

16. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed

    • Wendie D. den Brok
    • Caroline H. Speers
    • Caroline A. Lohrisch

    Epidemiology 20 December 2016 Pages: 549 - 556

    

17. Recurrence risk perception and quality of life following treatment of breast cancer

    • Sarah T. Hawley
    • Nancy K. Janz
    • Steven J. Katz

    Epidemiology 21 December 2016 Pages: 557 - 565

    

18. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

    • A. H. M. de Vries Schultink
    • X. Alexi
    • J. H. Beijnen

    Epidemiology 22 December 2016 Pages: 567 - 574

    

19. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results

    • Mary Pritzlaff
    • Pia Summerour
    • Holly LaDuca

    Epidemiology Open access 22 December 2016 Pages: 575 - 586

    

20. The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients

    • Yun Li
    • Allison W. Kurian
    • Timothy P. Hofer

    Epidemiology 23 December 2016 Pages: 587 - 595

    

21. Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene

    • A. Tavera-Tapia
    • L. Pérez-Cabornero
    • A. Osorio

    Brief Report 02 December 2016 Pages: 597 - 604

    

22. MicroRNA-567 dysregulation contributes to carcinogenesis of breast cancer, targeting tumor cell proliferation, and migration

    • Gloria Bertoli
    • Claudia Cava
    • Isabella Castiglioni

    Brief Report Open access 20 December 2016 Pages: 605 - 616

    

23. The effects of laterality in stage IV breast cancer patients at initial diagnosis; much work is needed!

    • Kadri Altundag

    Letter to the Editor 06 January 2017 Pages: 617 - 617

24. Breast cancer is a systemic disease rather than an anatomical process

    • Bernardo Amadeo Leone
    • Julieta Leone
    • José Pablo Leone

    Rebuttal Letter 09 January 2017 Pages: 619 - 619